摘要
CD4+CD25+FOXP3+调节性T细胞是具有特定表型和抑制功能的T淋巴细胞亚群,可通过多种方式抑制抗肿瘤免疫反应从启动到效应的整个阶段,在肿瘤免疫逃逸中起着重要作用。肿瘤患者体内调节性T细胞增多,不仅是一个普遍现象,而且对预后及疗效评价等多方面具有指导意义,是免疫治疗的新的有效靶点。
As a distinct T cell subset with acknowledged specific function and marker, CD4 ^＋ CD25 ^＋ FOXP3 ^＋ regulatory T cells are thought to dampen T-cell immunity and to be the main obstacle tempering antitumor immunotherapy. Accumulating evidence has confirmed an increased pool of regulatory T cells both in the peripheral blood and the tumor microenvironment of cancer patients, which are indicative of disease progression, response to therapy, invasive phenotype and prognosis. Therefore, manipulation of regulatory T cells-includlng depletion, blocking trafficking into tumors, or reducing their differentiation and suppressive mechanisms-and concomitant stimulation of effector T cells, systemically or locally in tumors, represent new strategies for cancer treatment.
出处
《中国癌症杂志》
CAS
CSCD
2007年第8期657-662,共6页
China Oncology
基金
教育部科学技术研究重点项目(No.107039)
关键词
肿瘤免疫
调节性T细胞
预后
治疗
tumor immunology
regulatory T cell
prognosis
treatment
